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The implementation of pharmacogenomics is increasingly 
relevant at the population level. Nearly 70% of Americans 
take at least one medication and more than 20% take five or 
more,1 with spending on medications projected to be over 
US$457 billion by 2019.2 Defined as the study of genetic 
variation associated with drug response, pharmacogenomics 
seeks to understand how genes affect the pharmacokinetics 
and pharmacodynamics of drugs.3 Pharmacogenomics allows 
drug therapy to be individualized based on genotypes, poten-
tially addressing the 20%–95% of variability in drug disposi-
tion that is genetics related.4
Clinical implementation of pharmacogenetic testing may 
improve patient outcomes by reducing side effects and 
improving treatment response.5 Currently, drug therapy for 
many conditions is plagued by unacceptable levels of adverse 
drug reactions, ineffectiveness, and poor adherence. Each 
year, adverse drug reactions are responsible for the death of 
approximately 100,000 patients6 and 5% of hospitalizations.7 
Adverse reactions are one of several reasons for poor medi-
cation adherence, which ultimately reduces drug efficacy 
and worsens the societal disease burden.8,9 Genomic science 
has the potential to change this picture. For many of the most 
commonly used drugs, the specific genetic variants that 
result in either toxic adverse reactions or sustained efficacy 
are now known.
Pharmacogenetically actionable medications are defined as 
those for which there is sufficient information to guide drug or 
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Abstract
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dosing changes in clinical practice. Over 160 medications now 
incorporate pharmacogenetic information on their labels,10 
and a subset of these have sufficient evidence to guide clinical 
practice changes based on an individual patient’s pharmacoge-
netic test results. For example, the Clinical Pharmacogenetic 
Implementation Consortium (CPIC) has produced 35 evi-
dence-based guidelines for gene and drug pairs to help clini-
cians understand how genetic test results should be used to 
optimize both individual medications (e.g. codeine and warfa-
rin) and classes of drugs (e.g. tricyclic antidepressants).11 
CPIC guidelines suggest alternative medications or higher or 
lower doses based on pharmacogenetic test results. However, 
only a limited number of institutions in the United States, 
Canada, and Europe have begun to implement clinical phar-
macogenetic testing to guide medication prescribing.11
In order to implement pharmacogenetic testing within a 
health care system, it is important to determine how many 
patients and clinics might be affected. Such knowledge is 
critical to identifying how and where to best direct resources 
for testing patients and educating providers about pharma-
cogenomics initiatives, particularly in resource constrained 
settings. Empirical data to answer these questions are some-
what limited. One study showed that 64% of patients seen in 
the primary care clinics of a large academic medical center 
had been prescribed at least one known pharmacogenomi-
cally actionable medication.12 Whether those results general-
ize to other clinics or to non-academic or underserved 
settings is unclear.
The study purpose was to evaluate the potential scope of 
implementing multi-drug pharmacogenetic testing in a large 
safety net health care system. Our aims were to (1) identify 
the number of patients exposed to at least one of 30 known 
pharmacogenomically actionable medications and (2) iden-
tify the number and types of clinics involved to best direct 
provider education efforts during implementation. Our guid-
ing questions were as follows: How many patients are 
exposed to known pharmacogenomically actionable medica-
tions? What are the age, race, and gender of those patients? 
In what clinics do patients receive care?
New contribution
This study extends research on the implementation of 
pharmacogenomics in several ways. To the best of our 
knowledge, it is the first to focus on a large, safety net 
health care system. Prior pharmacogenomic studies have 
focused on academic health centers12–15 which have greater 
resources for implementation. It is well documented that 
poverty is closely aligned with poor health, and that expen-
sive health care complications occur with greater fre-
quency in the underserved, who are at greater risk of 
emergency room visits, frequent hospital admissions,16 
and adverse outcomes from diseases and their treat-
ments.17–20 Thus, data from academic health centers may 
not generalize to safety net health care systems. Second, 
measuring the costs and benefit of pharmacogenetics test-
ing is challenging and requires an informatics infrastruc-
ture capable of measuring both financial costs and clinical 
outcomes. As a result, the business case for implementa-
tion of genomic and pharmacogenetic testing in large 
health care systems has not been persuasive.21,22 Data from 
our study will provide a better understanding of the poten-
tial scope of implementation of a multi-drug, multi-gene 
approach to help build the business case for implementa-
tion to help drive change. Third, we interpret our results in 
the context of health care providers’ educational needs. 
Gaps in clinician education have been identified as a bar-
rier to implementation of pharmacogenomics15 with one 
national survey indicating only 10% of nearly 400,000 
physicians felt appropriately informed about pharmacoge-
netic testing.23 No data are available on nurse practitioner 
knowledge. Identifying the estimated number and type of 
providers who are likely to encounter pharmacogenomi-
cally guided medication orders will also help drive imple-
mentation forward.
Conceptual model
This study is based on a three-step model for implementation 
of pharmacogenetic testing.15 Step 1, obtaining genomic 
data, requires clear understanding of the patient population, 
the genomic data storage needs, as well as the genes and 
variants to be screened. Having addressed the latter two 
points during planning, the current analysis was undertaken 
to better understand the patient population. Step 2 of the pro-
cess relates to interpreting genomic data which will be auto-
mated within our implementation system. Step 3, returning 
genomic data to providers, requires educated clinicians capa-
ble of acting upon pharmacogenetic test results. The current 
analysis of clinic encounters was designed to better under-
stand the number and type of providers likely to be touched 
by and require education about implementation. Thus, our 
analysis was designed to provide crucial data for Steps 1 and 
3 within the implementation process.
Methods
Design and data source—overview
This was a retrospective analysis of existing electronic medi-
cal record data from the Eskenazi Health System in 
Indianapolis, IN, that was judged to be an exempt study by 
the institutional review board office. As a result, no informed 
consent or authorization to use protected health information 
was required. Three sources of data were used. Some Eskenazi 
data (including medication-dispensing events) are housed in 
the Regenstrief Medical Record System (RMRS). There is 
also a computerized physician order entry system (Gopher).24 
Other Eskenazi data (number and locations of health care 
encounters, diagnoses, dates) are housed in Eskenazi Health’s 
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own clinical data repository. Pharmacogenetic testing has not 
been previously offered within this health care system.
Identification of medications
As part of the Implementing Genomics in Practice National 
Institutes of Health/National Human Genome Research 
Institute (IGNITE NIH/NHGRI)-funded project called 
INGENIOUS (INdiana GENomics Implementation: an 
Opportunity for the UnderServed), we identified 30 medica-
tions known to be pharmacogenomically actionable. All of 
the chosen medications had sufficient evidence to guide drug 
changes or dosing adjustments in practice. The targeted medi-
cations were based on extensive literature reviews of peer-
reviewed publications, Food and Drug Administration 
labeling, internal pre-publication data from our groups of sci-
entists, and a strong emphasis on guidelines published by 
CPIC, the Dutch Pharmacogenetics Working Group, and the 
Canadian Pharmacogenomics Network for Drug Safety. A 
working group composed of cross-functional team members 
representing clinical and scientific specialties reviewed the 
data, engaged in a series of face-to-face discussions over the 
period of a year, and reached consensus on the selection of 
targeted medications and relevant genes and variants to be 
studied. The working group members included pharmacoge-
neticists, clinical pharmacologists, the clinical laboratory 
director, and physicians from nephrology, cardiology, gastro-
enterology, infectious disease, oncology, pediatrics, obstet-
rics, geriatrics, and general internal medicine. Our focus on 
multiple drugs required a multi-gene approach since each 
drug is affected by specific genetic polymorphisms. The 
entire process allowed for informed decisions regarding clini-
cal and scientific evidence supporting each targeted medica-
tion. Because proton pump inhibitors are used commonly in 
this health care system, and risk of adverse events can to 
some extent be stratified based on indications, we limited the 
cohort with proton pump inhibitors to patients with 
International Classification of Diseases—Ninth Revision 
(ICD-9) diagnosis codes that reflected higher risk of adverse 
events.
Identification of patients
We sought to identify patients who had received a new pre-
scription for any one of the 30 targeted medications. The first 
inclusion criterion identified patients with at least one new 
(Gopher) order for any of the 30 medications of interest 
between 1 July 2013 and 30 June 2014. By “new” order, we 
meant no previous order for the same medication between 
April 2011 (when the current version of Gopher went online) 
and 30 June 2013. We then narrowed this “new” order cohort 
to those who had received their relevant new medication 
order at a care encounter site (outpatient, emergency, or inpa-
tient) on the main campus of Eskenazi Health (including 
Eskenazi Hospital), or at any Eskenazi mental health site in 
Indianapolis. This step excluded new medication orders at 
any of Eskenazi Health’s eight off-campus primary care sites 
in Indianapolis neighborhoods. We adopted this approach 
because our plan in the prospective trial is to recruit subjects 
on the main campus. Separately from using order data to 
define “new,” we also examined medication-dispensing data 
to define “new.” Medication-dispensing data were not 
directly linked to the encounter sites. Because medication 
orders were linked to the encounter sites (Gopher), we used 
medication orders in our primary analyses. We used medica-
tion-dispensing data as a secondary source, to help triangu-
late the order data to confirm the number of patients.
We then scrutinized how the medication records had actu-
ally been stored electronically, for the year 1 July 2013 to 30 
June 2014. We reviewed all 3349 orderable medication 
names in the Gopher system in order to find all possible 
forms, strengths, and combinations (n = 47) in which the 30 
medications of interest could have been ordered. We 
reviewed all 17,062 medication names stored in the RMRS, 
in order to find all forms, strengths, and combinations in 
which relevant dispensing events had been recorded for 
Eskenazi patients during that year. In this way, we identified 
many more records than Regenstrief initially provided us. 
For example, for codeine, Regenstrief initially provided only 
records containing the full-word “codeine,” but we knew to 
query for abbreviated forms such as “Acetaminophen-cod #4 
tablet.”
Once the patient cohort was identified, demographics 
contained in the medical record were abstracted. Data 
included age, gender, and race.
Number and types of clinic encounters
Similarly, for locations of care, we reviewed the way that all 
unique encounter locations had been stored in the Eskenazi 
system for patients on at least one of the 30 medications. We 
then winnowed this set of locations down to those on the 
main campus inpatient, outpatient, or emergency depart-
ment, or those within mental health services sites (outpatient 
or inpatient).
Results
A total of 7039 unique patients had received a new order for 
one or more of our targeted medications during the 12-month 
time period meeting our inclusion criteria. Patients represented 
diverse genders, ages, and races/ethnicities (see Table 1). 
Races/ethnicities shown in Table 1 were comparable to the 
adult patients seen within the health care institution during the 
same time period, the latter being 40% Black, 32% White, 2% 
Asian, 3% Hispanic, 4% mixed races, and 19% other/unknown. 
These patients had received a total of 8169 prescriptions, with 
20% of the patients receiving prescriptions for two or more of 
the targeted medications (see Table 1). These numbers suggest 
that each day on average, about 26 unique patients began a new 
4 SAGE Open Medicine
prescription for one or more of these pharmacogenetically 
actionable medications.
Table 2 shows the total number of prescriptions by medica-
tion. Tramadol, citalopram, and clopidogrel were the three 
most commonly prescribed overall. No prescriptions were 
seen for three of the targeted medications: cyclophosphamide, 
mercaptopurine, or rasburicase. Prescriptions were also rela-
tively rare (<15 Rx) for capecitabine, tacrolimus, and 
voriconazole.
Prescriptions originated across the health system in 73 
different care sites. Tramadol was among the three most 
commonly prescribed of the targeted medications across 
Table 1. Demographic characteristics of patients who received a new prescription for one or more known pharmacogenomically 
actionable medications.
(n = 7039)
Age (mean, SD) 51.0 (14.4)
Median  52.5
Range 21.1 to >89
Gender (n, %)
 Female 3943 (56%)
 Male 3096 (44%)
Race (n, %)
 Black 2858 (41%)
 White 3036 (43%)
 Asian 100 (1%)
 Hispanic 30 (<1%)
 Mixed 99 (1%)
 Other/unknown 916 (13%)
Number of targeted medications per patient (mean, SD) 1.2 (0.5)
Median (range) 1.0 (1 to 5)
Number of patients taking targeted medications
 1 of the targeted medications 5648 (80%)
 2 1173 (17%)
 3 185 (3%)
 4 30 (<1%)
 5 of the targeted medications 3 (<1%)
Table 2. Number of new prescriptions for each of the targeted medications.
Targeted medication No. of Rx Targeted medication No. of Rx
1. Amitriptyline 521 16. Mercaptopurine 0
2. Aripiprazole 215 17. Methotrexate 183
3. Atazanavir 111 18. Nortriptyline 216
4. Atomoxetine 19 19. Phenytoin 142
5. Azathioprine 94 20. PPIs 507
6. Capecitabine 14 21. Quetiapine 525
7. Citalopram 890 22. Rasburicase 0
8. Clopidogrel 820 23. Simvastatin 455
9. Codeine 467 24. Tacrolimus 12
10. Cyclophosphamide 0 25. Tenofovir 320
11. Doxepin 131 Tenofovir and efavirenz 188
12. Efavirenz 203 26. Thioguanine 0
13. Escitalopram 146 27. Tramadol 1388
14. Fluorouracil (systemic) 43 28. Venlafaxine 267
15. Glyburide 136 29. Voriconazole 10
 30. Warfarin 557
PPI: proton pump inhibitor.
PPI limited indications as noted in the “Methods” section.
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the emergency department, outpatient clinics, and inpa-
tient units (Figures 1–4). Overall, the largest number of 
prescriptions for each targeted medication originated in 
the outpatient, non-mental health clinics with these excep-
tions: (1) clopidogrel, codeine, and phenytoin (emergency 
department) and (2) aripiprazole and quetiapine (mental 
health care sites). In total, there were 73 different care 
sites.
Figure 5 shows the complex trajectory of health care 
encounters and related prescriptions at different clinical 
encounter sites for one of the three patients taking five of 
the targeted medications. During the year, this patient 
made 28 health care visits to four different care locations, 
although all prescriptions originated in the emergency 
department.
Discussion
The goal of personalized medicine is to implement 
advances in biomarker pharmacology, molecular diagnos-
tics, and genomics to improve public health. For the full 
benefits of this science to be realized, it is critical that 
scientific advances made in experimental settings and on a 
small scale be extended to community practice and that a 
business case can be made to support such dissemination. 
Furthermore, it is important that key innovations be 
extended beyond individual hospital settings to large 
health care systems, especially those that include under-
served populations.
In terms of clinical implementation, our findings showed 
that a multi-gene, multi-drug pharmacogenetic testing 
approach would be relevant to a large number of patients 
who are diverse in terms of age, gender, race, and clinical 
settings. These data strengthen the case for system-wide 
rather than select clinic-based implementation, since the lat-
ter would be inadequate for capturing the target population 
and inefficient since patients are seen across many care set-
tings. Our methods for identifying patients using existing 
electronic medical record data are a cost-efficient means 
that others can use to evaluate and model subsequent imple-
mentation costs. For example, our trial will be based on 
patients who received an order for a target medication, 
rather than on pre-emptive genotyping. Our data can be 
used to model the most cost-efficient frequency for running 
tests based on the number of samples per day likely to be 
Figure 1. Medication prescriptions within the emergency 
department. Figure shows number of prescriptions originating 
in the emergency department with tramadol, clopidogrel, and 
codeine being the three most common. No patients were 
prescribed thioguanine.
Figure 2. Medication prescriptions within outpatient, non-
mental health clinics. Figure shows number of prescriptions 
originating in non-mental health specific outpatient clinics with 
tramadol, amitriptyline, and citalopram being the three most 
common. No patients were prescribed thioguanine.
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received and cost variations related to running small, 
medium, or large batches of samples. Our data could also be 
useful for those planning pre-emptive genotyping for one or 
more of the targeted medications.
Implementation requires well-educated prescribers. 
Our data suggest that educational efforts should be sys-
tem-wide and ongoing to address any changes or turnover 
in prescribers. Such large-scale efforts are likely to require 
asynchronous, cost-efficient educational modules (e.g. 
web-based) that are either mandatory or incentivized (e.g. 
continuing education credits). In addition, our case study 
data can be used during educational efforts to illustrate the 
potential complexity of incorporating and acting upon 
pharmacogenetic test results. They also suggest that edu-
cation include strategies for communicating pharmacoge-
netic information during handoffs and care transitions. Our 
data suggest that wide-scale prescriber education efforts 
that cross different care encounter sites be fully considered 
during planning so that they do not become a hidden or 
unexpected cost.
Study findings should be interpreted in light of some limi-
tations. Although the findings provide an important perspec-
tive from a safety net rather than tertiary academic health 
care setting, the data are from a single system and may not be 
generalizable to other safety net systems. The reason why 
several of the targeted medications had not been ordered dur-
ing the previous year is unclear. In addition, because findings 
are based on the US health care system, they may not gener-
alize to other countries.
Conclusion
Findings document the potential scope of implementing 
multi-gene, multi-drug pharmacogenetic testing in a large 
safety net health care system. A large number and diversity 
of patients and clinics would be directly affected by imple-
mentation indicating the need for large-scale education of 
prescribers and other personnel involved in medication dis-
pensing and handling.
Figure 3. Medication prescriptions within inpatient, non-mental 
health clinics. Figure shows number of prescriptions originating 
in non-mental health specific inpatient clinics with clopidogrel, 
warfarin, and tramadol being the three most common. No 
patients were prescribed thioguanine.
Figure 4. Medication prescriptions within inpatient and 
outpatient mental health specific settings. Figure shows number 
of prescriptions originating in mental health specific outpatient 
clinics and inpatient units with citalopram, quetiapine, and 
aripiprazole being the three most common. No patients were 
prescribed thioguanine.
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